Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

Aviva Investors has flagged three of its funds as failing to deliver value for customers, though said no changes will be made ...

Novo Nordisk sues KBP Biosciences, seeking $830 million in damages over Ocedurenone, alleging data misrepresentation that led ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...

Tariffs targeted at countries — reciprocal or regular — will likely be paid by multinational companies, dampening the outlook ...

A summary of current health news highlights a bird flu outbreak in Canada, halted HIV vaccine trials in South Africa, a legal ...